A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicenter study designed to evaluate the maximum
tolerated, safety, tolerability and PK of oral YY-15293 in patients with advanced solid
tumors with a KRAS G12C mutation, to confirm the recommended phase 2 dose of YY-15293, and to
obtain preliminary efficacy information in patients with advanced non-small cell lung cancer
(NSCLC) with a KRAS G12C mutation.